Abstract
To the editor: The prevalence of anxiety disorders in coronary heart disease (CHD) is 10-23%. Approximately 50% of CHD patients with a depressive disorder also have an anxiety disorder. The high prevalence of anxiety disorders, irrespective of the risk for adverse cardiovascular prognosis, underscores the need to provide comprehensive anxiety treatment in patients with CHD. A recent paper in Psychosomatics (in this issue) attempts to systematically review randomized controlled trials (RCTs) on this important topic, however, there are numerous limitations to the review’s focus, validity, and utility to clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 623-624 |
| Journal | Psychosomatics |
| Volume | 59 |
| Issue number | 6 |
| Early online date | 16 Apr 2018 |
| DOIs | |
| Publication status | Published - Nov 2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Much a Review About Nothing: A Comment on the Treatment of Anxiety in Patients With Coronary Heart Disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver